Search Results
Results found for "Addex Therapeutics"
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Leverage this model to stay ahead of therapeutic complexity.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
indicated by the fact that about 40% of all drugs currently used in clinical practice mediate their therapeutic
- Rescue of Cell Surface Expression and Signaling of Mutant Follicle-Stimulating Hormone Receptors
advancing the understanding of the effects of genetic mutations on GPCR function and provide a proof of therapeutic
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
cognate positions across GPCR paralogs opens a window into cancer mechanisms and potential approaches to therapeutics
- 📰 GPCR Weekly News, October 9 to 15, 2023
Tethered Ligands that Target the µ-Opioid Receptor Design and Synthesis of Novel GPR139 Agonists with Therapeutic
- Your GPCR Program Decisions Depend on Good Data Interpretation
drug discovery; new strategies for inflammatory disease treatment; growth strategies from Tectonic Therapeutics
- 📰 GPCR Weekly News, May 15 to 21, 2023
Hopkins, Exscientia’s founder and CEO was elected a Fellow of the Academy of Medical Sciences Structure Therapeutics
- 📰 GPCR Weekly News - January 2 to 8, 2023
Enter into Multitarget Antibody Discovery Research Collaboration Neurocrine Biosciences and Voyager Therapeutics
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces
- 📰 GPCR Weekly News, March 18 to 24, 2024
Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease (IBD) Domain Therapeutics
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
implications for drug development, as targeting these non-cognate interactions could lead to novel therapeutic
- Understanding Enzyme Inhibition In GPCR Discovery Programs
When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design.
- Interacting binding insights and conformational consequences of the differential activity of...
way for understanding the CBD pharmacology at a molecular level and aid in harnessing its potential therapeutic
- Dr. GPCR University registration is now open! Secure your spot now!
the atomic-level quaternary structure of short-lived GPCR oligomers in live cells Industry News Confo Therapeutics
- GPCR Collaboration: From Models to Medicine
They offer extraordinary therapeutic promise —but their complexity makes them one of the hardest targets
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
When a drug outlives its exposure , toxic interactions can be just as persistent as therapeutic ones.
- Exploring the Breakthroughs in GPCR Research
GPCRs remain one of the most prolific and fertile therapeutic drug targets.
- GPCR News Flash! Top Updates You Can't-Miss! + University CheatSheet is finally available! ❄ Dec 2 - 8, 2024
Pharmacology GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic
- 📰 GPCR Weekly News, October 16 to 22, 2023
potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology, Domain Therapeutics
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
understanding how serotonin receptors, one of the largest subfamilies of class A GPCRs and potential therapeutic
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
revolution of biased signalling of GPCRs comes the possibility of designing drugs that selectively activate therapeutically analyzing drug-target interactions and disease pathways, AI can identify potential candidates that may have therapeutic
- 📰 GPCR Weekly News, January 23 to 29, 2023
Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics
- Advantages of Fluorescent Probes in GPCR Assays
GPCRs pose a critical challenge in drug discovery: a vast therapeutic potential with many targets yet
- 📰 GPCR Weekly News, December 4 to 10, 2023
Muscarinic Agonist Candidates in Phase 1 Clinical Studies AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics
- 📰 GPCR Weekly News - January 9 to 15, 2023
Foundation is awarding DKK 174 million in grants to seven ‘mind-bending’ research collaborations GPCR Therapeutics
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
competitive edge: Learn to leverage restricted diffusion and rebinding to create drugs with longer therapeutic
- 📰 GPCR Weekly News, February 13 to 19, 2023
GPCR Binders, Drugs, and more Novel targets for potential therapeutic use in Diabetes mellitus.
- HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G 1/S cycle
modulating autophagy and the CDKN1B-CDK2-CCNE1-E2F1 axis and indicate that ARRB1 may be a potential therapeutic
- 📰 GPCR Weekly News, February 5 to 11, 2024
Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 Domain Therapeutics












